AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs

AHA to Eli Lilly and Company Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Key Resources

Related Resources

Letter/Comment
AHA Submits Comments on CMS Guidance For Medicare Drug Price Negotiation Program
Public
Letter/Comment
AHA Letter to House Energy and Commerce Committees on Value of 340B Program
Public
Action Alert
Contact your Representative Prior to June 4 House Subcommittee Hearing on 340B
Member Non-Fed
Advisory
HRSA Finalizes 340B Administrative Dispute Resolution Process
Member
Letter/Comment
AHA Responds to Senate RFI on the SUSTAIN 340B Act Draft
Guides/Reports
The 340B Drug Pricing Program